Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Y-3 injection for acute ischemic stroke
ChiCTR2400081662Phase 2Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of loberamisal in ischemic stroke (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of subjects with mRS score less than or equal to 1 at Day 90. Started Mar 2024; status: completed.
02
Drugs
loberamisal
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400081662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081662.